Roche's checkpoint inhibitor delivers mixed results in lung cancer study

Roche's checkpoint inhibitor delivers mixed results in lung cancer study

STAT Plus: Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study

By ADAM FEUERSTEIN

ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME

The new combination treatment — tiragolumab plus Tecentriq — only showed a meaningful benefit in a subset of lung cancer patients.

READ MORE